Innovation Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.ipharminc.com
Clinical Trials
5
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:1
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (80.0%)Phase 1
1 (20.0%)A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04784897
- Locations
- 🇷🇺
IPI Investigator Site, Saint Petersburg, Russian Federation
A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04240223
- Locations
- 🇬🇧
BDD Pharma Ltd, Glasgow, Scotland, United Kingdom
A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03042702
- Locations
- 🇺🇸
Cancer Research, Dallas, Texas, United States
Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
Phase 2
Completed
- Conditions
- Chronic Stable Plaque Psoriasis
- Interventions
- Drug: PlaceboDrug: 300 mg (150 mg BID)Drug: 400 mg (200 mg BID)
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT02949388
- Locations
- 🇺🇸
Study Site, Webster, Texas, United States
🇺🇸Study Center, Charlottesville, Virginia, United States
🇺🇸Clinical Study Site, San Antonio, Texas, United States
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck NeoplasmsMucositis
- Interventions
- Other: Placebo
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Innovation Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02324335
News
No news found